These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18075301)

  • 1. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients.
    Alfonso S; Diaz RM; de la Torre A; Santiesteban E; Aguirre F; Pérez K; Rodríguez JL; Barroso Mdel C; Hernández AM; Toledo D; Gabri MR; Alonso DF; Viada C; Gómez RE; Suárez E; Vazquez AM; Perez R; Macias AE
    Cancer Biol Ther; 2007 Dec; 6(12):1847-52. PubMed ID: 18075301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.
    Neninger E; Díaz RM; de la Torre A; Rives R; Díaz A; Saurez G; Gabri MR; Alonso DF; Wilkinson B; Alfonso AM; Combet T; Pérez R; Vázquez AM
    Cancer Biol Ther; 2007 Feb; 6(2):145-50. PubMed ID: 17218777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.
    Hernández AM; Toledo D; Martínez D; Griñán T; Brito V; Macías A; Alfonso S; Rondón T; Suárez E; Vázquez AM; Pérez R
    J Immunol; 2008 Nov; 181(9):6625-34. PubMed ID: 18941253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.
    Alfonso M; Díaz A; Hernández AM; Pérez A; Rodríguez E; Bitton R; Pérez R; Vázquez AM
    J Immunol; 2002 Mar; 168(5):2523-9. PubMed ID: 11859147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model.
    Fuentes D; Avellanet J; Garcia A; Iglesias N; Gabri MR; Alonso DF; Vazquez AM; Perez R; Montero E
    Breast Cancer Res Treat; 2010 Apr; 120(2):379-89. PubMed ID: 19377876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides.
    Díaz A; Alfonso M; Alonso R; Saurez G; Troche M; Catalá M; Díaz RM; Pérez R; Vázquez AM
    Clin Immunol; 2003 May; 107(2):80-9. PubMed ID: 12763476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self-matter.
    Hernández AM; Rodríguez M; López-Requena A; Beausoleil I; Pérez R; Vázquez AM
    Immunobiology; 2005; 210(1):11-21. PubMed ID: 16076030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma.
    Diaz Y; Gonzalez A; Lopez A; Perez R; Vazquez AM; Montero E
    Cancer Immunol Immunother; 2009 Jul; 58(7):1117-28. PubMed ID: 19066887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions.
    López-Requena A; Mateo de Acosta C; Pérez A; Valle A; Lombardero J; Sosa K; Pérez R; Vázquez AM
    Hybrid Hybridomics; 2003 Aug; 22(4):235-43. PubMed ID: 14511569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
    Alfonso S; Valdés-Zayas A; Santiesteban ER; Flores YI; Areces F; Hernández M; Viada CE; Mendoza IC; Guerra PP; García E; Ortiz RA; de la Torre AV; Cepeda M; Pérez K; Chong E; Hernández AM; Toledo D; González Z; Mazorra Z; Crombet T; Pérez R; Vázquez AM; Macías AE
    Clin Cancer Res; 2014 Jul; 20(14):3660-71. PubMed ID: 24788102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.
    Hernández AM; Rodríguez N; González JE; Reyes E; Rondón T; Griñán T; Macías A; Alfonso S; Vázquez AM; Pérez R
    J Immunol; 2011 Mar; 186(6):3735-44. PubMed ID: 21300821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
    Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
    Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Come forth 1E10 anti-idiotype vaccine: delivering the promise to immunotherapy of small cell lung cancer.
    Manjili MH
    Cancer Biol Ther; 2007 Feb; 6(2):151-2. PubMed ID: 17426436
    [No Abstract]   [Full Text] [Related]  

  • 14. Gangliosides, Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system.
    López-Requena A; De Acosta CM; Moreno E; González M; Puchades Y; Talavera A; Vispo NS; Vázquez AM; Pérez R
    Mol Immunol; 2007 Jan; 44(4):423-33. PubMed ID: 16581129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
    Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
    Bhattachary-Chatterjee M; Nath Baral R; Chatterjee SK; Das R; Zeytin H; Chakraborty M; Foon KA
    Cancer Immunol Immunother; 2000 Jun; 49(3):133-41. PubMed ID: 10881692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.